To the Editor, Postpartum-acquired hemophilia A is a rare and potentially severe complication of pregnancy caused by an autoantibody against factor VIII [1] . Acquired factor VIII deficiency is associated with autoimmune conditions, neoplastic diseases, drug hypersensitivity, and pregnancy. A retrospective study analyzed 51 published cases of postpartum factor VIII inhibitors, with regard to the outcome according to treatment [2] . The annual incidence of acquired hemophilia is 0.2-1/1,000,000 and it is difficult to diagnose. Most patients present with major hemorrhage and the mortality rate is about 22% [3] [4] [5] .
A 20-year-old female in the postpartum period presented to the hospital with vaginal hemorrhage that had begun 20 d earlier. Examination of the patient showed that there were no obstetrical or gynecologic pathologies, or acute or chronic diseases causing the hemorrhage. The patient's laboratory data are summarized in the Table 1 . The patient's activated partial thromboplastin time (APTT) was 68.4 s. A mixing study using a 50:50 mixture of the patient's plasma and control plasma showed no correction suggesting the presence of an inhibitor. The patient's factor VIII inhibitor level was 2.5 BU mL -1 (normal: <0.6 BU mL Intravenous immunoglobulin (IVIG, 400 mg kg -1 for 5 d) and IV methylprednisolone (60 mg d -1 for 1 week) was given (as recommended) to eliminate the inhibitor [6] . At follow-up 7 d after the initiation of treatment the patient was clinically stable with a normal aPTT. Methylprednisolone was initiated at 50 mg d -1 8 d after the start of the initial treatment, and was then gradually tapered and stopped over the course of 6 weeks. The patient was discharged from the hospital 15 days after treatment was initiated. Factor VIII inhibitor was 0.55 BU 4 weeks after delivery. The patient's postpartum hemorrhage was attributed to the presence of acquired factor VIII inhibitor.
Factor VIII inhibitor can be seen in healthy pregnant women without a history of bleeding. Prolonged aPTT and normal PTT is the hallmark of laboratory diagnosis. The objectives of therapy are control of bleeding and elimination of the inhibitor [5, 7] . Treatment strategies to control active bleeding include the use of factor VIII concentrates, activated prothrombin complex concentrates (anti-inhibitor coagulant complex, Feiba, Autoplex T), and recombinant human factor VIIa [6, 8, 9] . Elimination of factor VIII inhibitor requires the use of immunosuppressive modalities. A prospective randomized trial evaluated the efficacy of prednisone and cyclophosphamide alone, and the combination of both drugs in 31 non-hemophilic patients with factor VIII antibodies. All patients initially received prednisone (1 mg·kg -1 ·d -1 p.o.) for 3 weeks and the antibody disappeared in 10 of the 31 participants (32%) during the initial course of prednisone [10] . Another option for the treatment of acquired factor VIII inhibitors is administration of IVIG [11] . Written informed consent was obtained from the patient for publication.
Acquired hemophilia A is a rare and often fatal disorder. Because of difficulties and misdiagnosis delays in diagnosis and treatment are common. As such, whenever acquired hemophilia A-with or without bleeding is suspected immediate consultation with a hemophilia experienced in the management of inhibitors should be initiated.
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